|
1
|
He Y, Mou J, Luo D, Gao B and Wen Y:
Primary malignant melanoma of the breast: A case report and review
of the literature. Oncol Lett. 8:238–240. 2014.PubMed/NCBI
|
|
2
|
Li FY, Wu SG, Zhou J, Sun JY, Lin Q, Lin
HX, Guan XX and He ZY: Prognostic value of Ki-67 in breast cancer
patients with positive axillary lymph nodes: A retrospective cohort
study. PLoS One. 9:e872642014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), . Effects of chemotherapy and
hormonal therapy for early breast cancer on recurrence and 15-year
survival: An overview of the randomised trials. Lancet.
365:1687–1717. 2005. View Article : Google Scholar
|
|
4
|
Fornier M and Fumoleau P: The paradox of
triple negative breast cancer: Novel approaches to treatment.
Breast J. 18:41–51. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Millikan RC, Newman B, Tse CK, Moorman PG,
Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT,
et al: Epidemiology of basal-like breast cancer. Breast Cancer Res
Treat. 109:123–139. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
D'Ippolito E and Iorio MV: MicroRNAs and
triple negative breast cancer. Int J Mol Sci. 14:22202–22220. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McNamara KM, Yoda T, Nurani AM, Shibahara
Y, Miki Y, Wang L, Nakamura Y, Suzuki K, Yang Y, Abe E, et al:
Androgenic pathways in the progression of triple-negative breast
carcinoma: A comparison between aggressive and non-aggressive
subtypes. Breast Cancer Res Treat. 145:281–293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jang NY, Kim DH, Cho BJ, Choi EJ, Lee JS,
Wu HG, Chie EK and Kim IA: Radiosensitization with combined use of
olaparib and PI-103 in triple-negative breast cancer. BMC Cancer.
15:892015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu P, Tang H, Chen B, He Z, Deng M, Wu M,
Liu X, Yang L, Ye F and Xie X: miR-26a suppresses tumour
proliferation and metastasis by targeting metadherin in triple
negative breast cancer. Cancer Lett. 357:384–392. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bisso A, Faleschini M, Zampa F, Capaci V,
De Santa J, Santarpia L, Piazza S, Cappelletti V, Daidone M, Agami
R and Del Sal G: Oncogenic miR-181a/b affect the DNA damage
response in aggressive breast cancer. Cell Cycle. 12:1679–1687.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma F, Li H, Wang H, Shi X, Fan Y, Ding X,
Lin C, Zhan Q, Qian H and Xu B: Enriched CD44(+)/CD24(−) population
drives.the aggressive phenotypes presented in triple-negative
breast cancer (TNBC). Cancer Lett. 353:153–159. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
van Roy F: Beyond E-cadherin: Roles of
other cadherin superfamily members in cancer. Nat Rev Cancer.
14:121–134. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berx G and van Roy F: Involvement of
members of the cadherin superfamily in cancer. Cold Spring Harb
Perspect Biol. 1:a0031292009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Andrews JL, Kim AC and Hens JR: The role
and function of cadherins in the mammary gland. Breast Cancer Res.
14:2032012. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gheldof A and Berx G: Cadherins and
epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci.
116:317–336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Philippova M, Joshi MB, Kyriakakis E,
Pfaff D, Erne P and Resink TJ: A guide and guard: The many faces of
T-cadherin. Cell Signal. 21:1035–1044. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guillaume E, Comunale F, Do Khoa N,
Planchon D, Bodin S and Gauthier-Rouvière C: Flotillin microdomains
stabilize cadherins at cell-cell junctions. J Cell Sci.
126:5293–5304. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Adachi Y, Takeuchi T, Nagayama T, Ohtsuki
Y and Furihata M: Zeb1- mediated T-cadherin repression increases
the invasive potential of gallbladder cancer. FEBS Lett.
583:430–436. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Philippova M, Joshi MB, Pfaff D,
Kyriakakis E, Maslova K, Erne P and Resink TJ: T-cadherin
attenuates insulin dependent signalling, eNOS activation, and
angiogenesis in vascular endothelial cells. Cardiovasc Res.
93:498–507. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maslova K, Kyriakakis E, Pfaff D, Frachet
A, Frismantiene A, Bubendorf L, Ruiz C, Vlajnic T, Erne P, Resink
TJ and Philippova M: EGFR and IGF-1R in regulation of prostate
cancer cell phenotype and polarity: Opposing functions and
modulation by T- cadherin. FASEB J. 29:494–507. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Makarla PB, Saboorian MH, Ashfaq R,
Toyooka KO, Toyooka S, Minna JD, Gazdar AF and Schorge JO: Promoter
hypermethylation profile of ovarian epithelial neoplasms. Clin
Cancer Res. 11:5365–5369. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tang Y, Dai Y and Huo J: Decreased
expression of T-cadherin is associated with gastric cancer
prognosis. Hepatogastroenterology. 59:1294–1298. 2012.PubMed/NCBI
|
|
24
|
Toyooka S, Toyooka KO, Harada K, Miyajima
K, Makarla P, Sathyanarayana UG, Yin J, Sato F, Shivapurkar N,
Meltzer SJ and Gazdar AF: Aberrant methylation of the CDH13
(H-cadherin) promoter region in colorectal cancers and adenomas.
Cancer Res. 62:3382–3386. 2002.PubMed/NCBI
|
|
25
|
Li DL, Zhang ZQ, Chen SH, Zhang SA, Fang
J, Lin ZQ, Zhang X and Jiang Y: Expression of T-cadherin in
hepatocellular carcinoma and its relationship with relapse and
metastasis of tumor. Med J Chin PLA. 40:315–318. 2015.
|
|
26
|
Lin Y, Sun G, Liu X, Chen Y and Zhang C:
Clinical significance of T-cadherin tissue expression in patients
with bladder transitional cell carcinoma. Urol Int. 86:340–345.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takeuchi T, Misaki A, Chen BK and Ohtsuki
Y: H-cadherin expression in breast cancer. Histopathology.
35:87–88. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ciatto C, Bahna F, Zampieri N,
VanSteenhouse HC, Katsamba PS, Ahlsen G, Harrison OJ, Brasch J, Jin
X, Posy S, et al: T-cadherin structures reveal a novel adhesive
binding mechanism. Nat Struct Mol Biol. 17:339–347. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Andreeva AV and Kutuzov MA: Cadherin 13 in
cancer. Genes Chromosomes Cancer. 49:775–790. 2010.PubMed/NCBI
|
|
30
|
Ellmann L, Joshi MB, Resink TJ, Bosserhoff
AK and Kuphal S: BRN2 is a transcriptional repressor of CDH13
(T-cadherin) in melanoma cells. Lab Invest. 92:1788–1800. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee SW: H-cadherin, a novel cadherin with
growth inhibitory functions and diminished expression in human
breast cancer. Nat Med. 2:776–782. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Feng W, Orlandi R, Zhao N, Carcangiu ML,
Tagliabue E, Xu J, Bast RC Jr and Yu Y: Tumor suppressor genes are
frequently methylated in lymph node metastases of breast cancers.
BMC Cancer. 10:3782010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Toyooka KO, Toyooka S, Virmani AK,
Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD and Gazdar AF:
Loss of expression and aberrant methylation of the CDH13
(H-cadherin) gene in breast and lung carcinomas. Cancer Res.
61:4556–4560. 2001.PubMed/NCBI
|
|
34
|
Bradshaw SH, Pidutti D, Gravel DH, Song X
and Robertson SJ: Predicting OncoDX recurrence scores with
immunohistochemical markers: effect of stromelysin. Appl
Immunohistochem Mol Morphol. 23:26–30. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kong DD, Yang J, Li L, Wang W, Chen YN,
Wang SB and Zhou YZ: T-cadherin association with
clinicopathological features and prognosis in axillary lymph
node-positive breast cancer. Breast Cancer Res Treat. 150:119–126.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cavusoglu A Celebiler, Kilic Y, Saydam S,
Canda T, Başkan Z, Sevinc AI and Sakizli M: Predicting invasive
phenotype with CDH1, CDH13, CD44, and TIMP3 gene expression in
primary breast cancer. Cancer Sci. 100:2341–2345. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qasim BJ, Ali HH and Hussein AG:
Immunohistochemical expression of matrix metalloproteinase-7 in
human colorectal adenomas using specified automated cellular image
analysis system: A clinicopathological study. Saudi J
Gastroenterol. 19:23–27. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cimino-Mathews A, Hicks JL, Illei PB,
Halushka MK, Fetting JH, De Marzo AM, Park BH and Argani P:
Androgen receptor expression is usually maintained in initial
surgically resected breast cancer metastases but is often lost in
end-stage metastases found at autopsy. Hum Pathol. 43:1003–1011.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lebok P, Öztürk M, Heilenkötter U,
Jaenicke F, Müller V, Paluchowski P, Geist S, Wilke C, Burandt E,
Lebeau A, et al: High levels of class III β-tubulin expression are
associated with aggressive tumor features in breast cancer. Oncol
Lett. 11:1987–1994. 2016.PubMed/NCBI
|
|
40
|
Tao Y, Mao J, Zhang Q and Li L:
Overexpression of Hedgehog signaling molecules and its involvement
in triple-negative breast cancer. Oncol Lett. 2:995–1001.
2011.PubMed/NCBI
|
